
    
      Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The
      study consisted of two consecutive single-dose treatment periods separated by a washout
      period of 14 days or more. A total of twenty-eight (28) healthy volunteers received a single
      dose of 50 mg OPC, orally.
    
  